Drug Profile

AZP 3813

Alternative Names: AZP-3813

Latest Information Update: 18 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PeptiDream
Developer Amolyt Pharma
Class Bicyclic peptides; Macrocyclic compounds; Peptides
Mechanism of Action Somatotropin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Acromegaly

Most Recent Events

15 Jul 2024 Amolyt Pharma has been acquired by AstraZeneca
01 Jun 2024 Pharmacodynamics data from a preclinical trial in Acromegaly presented at the 106^thAnnual Meeting of the Endocrine Society (ENDO-2024)
01 Jun 2024 Pharmacokinetics, pharmacodynamics and adverse events data from the phase I trial in Acromegaly presented at the 106th Annual Meeting of the Endocrine Society (ENDO-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com